Shots:

• The PHYOX 3 OLE study involves assessing of nedosiran in participants aged ≥6yrs. with PH1 or PH2 who have participated in any previous PHYOX clinical development program trial as well as their siblings aged 6-18yrs. with PH
• All participants regardless of PH subtype- achieved normal or near-normal Uox excretion @day180- 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion at one or more visits- 62% participants (70% & 33% with PH1 & PH2) demonstrated normalized Uox excretions on at least three consecutive visits- maximum reduction in Uox excretion (70.9%)
• Nedosiran is an investigational candidate in development for the treatment of all three known types of PH – PH1- PH2- and PH3- act by inhibiting the LDH enzyme

 ­ Ref: Dicerna | Image: PRNewswire